Caris Life Sciences, Inc. (CAI) Income Statement

The steep sequential ramp through 2025 suggests a combination of rising clinical case volume and possibly lumpy biopharma milestone recognition, since the 2025Q4 peak was followed by sequential declines. The 27% year-over-year figure in the latest quarter indicates growth is durable but decelerating, which investors should monitor for whether volume gains are offsetting pricing or reimbursement pressure. Without a disclosed split between clinical and pharma revenue, the durability of the top-line trend cannot be fully verified from the provided data.

A gross margin in the mid-60s is respectable for a molecular profiling laboratory, suggesting reasonable unit economics on tests and data services. However, SG&A of $129.1M against $182.3M of gross profit in 2026Q3 leaves little room for error, and the thin operating spread implies that commercial and administrative scaling has not yet produced meaningful leverage. The margin structure is therefore highly sensitive to any reimbursement compression or cost inflation.

The fact that SG&A is scaling roughly in line with revenue suggests the business has not yet entered a phase where fixed commercial infrastructure is being spread across a larger base. Operating income swung from negative in 2025Q1 to positive in later periods, which is encouraging, but the magnitude remains modest relative to revenue. Investors should watch whether SG&A growth decouples from revenue growth in coming quarters, as this is the key test of whether the growth narrative converts into profit.